EXV4:XETRA:XETRA-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 118.64

Change

-0.04 (-0.03)%

Market Cap

USD 0.70B

Volume

4.76K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-22 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.34 (+0.69%)

USD 509.68B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.12 (+0.76%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.22 (+0.86%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.10 (+0.37%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.12 (+0.51%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

+1.72 (+1.21%)

USD 100.74B
JARI:XETRA Amundi Index Solutions - Amund..

+0.38 (+0.88%)

USD 100.71B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.38 (+0.77%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-0.70 (-0.13%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.19 (+0.87%)

USD 79.79B

ETFs Containing EXV4:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.37% 78% C+ 77% C+
Dividend Return 0.25% 24% F 12% F
Total Return 12.62% 79% B- 77% C+
Trailing 12 Months  
Capital Gain 9.22% 43% F 47% F
Dividend Return 0.48% 28% F 12% F
Total Return 9.70% 43% F 47% F
Trailing 5 Years  
Capital Gain 50.56% 64% D 66% D+
Dividend Return 6.21% 63% D 36% F
Total Return 56.77% 69% C- 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 6.25% 59% D- 58% F
Dividend Return 7.16% 63% D 60% D-
Total Return N/A 56% F 42% F
Risk Return Profile  
Volatility (Standard Deviation) 8.35% 68% D+ 75% C
Risk Adjusted Return 85.85% 94% A 94% A
Market Capitalization 0.70B 73% C 65% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike